Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics


Alnylam Pharmaceuticals, Inc. (ALNY)

Today's Latest Price: $131.90 USD

5.35 (-3.90%)

Updated Jun 4 4:00pm

Add ALNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ALNY Stock Summary

  • ALNY has a higher market value than 89.66% of US stocks; more precisely, its current market capitalization is $15,758,928,475.
  • With a price/sales ratio of 55.11, Alnylam Pharmaceuticals Inc has a higher such ratio than 96.62% of stocks in our set.
  • Revenue growth over the past 12 months for Alnylam Pharmaceuticals Inc comes in at 231.31%, a number that bests 97.13% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Alnylam Pharmaceuticals Inc, a group of peers worth examining would be MXIM, SWKS, GNTX, XLNX, and BGNE.
  • ALNY's SEC filings can be seen here. And to visit Alnylam Pharmaceuticals Inc's official web site, go to www.alnylam.com.
ALNY Daily Price Range
ALNY 52-Week Price Range

ALNY Stock Price Chart More Charts


ALNY Price/Volume Stats

Current price $131.90 52-week high $151.84
Prev. close $137.25 52-week low $68.00
Day low $131.11 Volume 623,494
Day high $139.03 Avg. volume 794,266
50-day MA $130.02 Dividend yield N/A
200-day MA $109.60 Market Cap 15.14B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.


ALNY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Getting Bullish

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 4, 2020

Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that seven patient advocacy groups will receive supportive funding as part of the company’s second annual Advocacy for Impact grants program. The global competitive grants program aims to inspire patient advocacy groups to develop solutions that address critical unmet needs among the hereditary transthyretin-mediated (hATTR) amyloidosis, acute hepatic porphyria (AHP) and primary hyperoxaluria type 1 (PH1) rare disease communities.

Yahoo | June 2, 2020

Alnylam to host webcast on Illuminate-A study of lumasiran on June 7

Alnylam Pharmaceuticals ([[ALNY]] -0.9%) will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, at 8:30 am ET.The clinical data will be presented at the European Renal Association-European Dialysis and Transplant Association International Congress being held June 6-9 as a...

Seeking Alpha | June 1, 2020

Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, 2020 at 8:30 am ET. Lumasiran is an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The clinical data will be presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held June 6-9 as a virtual event.

Yahoo | June 1, 2020

Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA

Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.

Yahoo | May 27, 2020

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -6.61%
3-mo 16.32%
6-mo 6.58%
1-year 86.96%
3-year 88.62%
5-year 0.42%
YTD 14.53%
2019 57.96%
2018 -42.61%
2017 239.34%
2016 -60.23%
2015 -2.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8453 seconds.